Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies

被引：35

作者：

Burger, David M. ^{[1
]}

机构：

[1] 864 Radboud Univ Nijmegen Med Ctr, Dept Pharm, NL-6525 GA Nijmegen, Netherlands

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2010年 / 6卷 / 09期

关键词：

AIDS; antiretroviral agents; HIV integrase; raltegravir; INTEGRASE INHIBITOR RALTEGRAVIR; TREATMENT-NAIVE PATIENTS; TREATMENT-EXPERIENCED PATIENTS; HIV-INFECTED PATIENTS; COMBINATION THERAPY; CEREBROSPINAL-FLUID; PLASMA-LEVELS; SAFETY; RITONAVIR; EFFICACY;

D O I：

10.1517/17425255.2010.513383

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Importance of the field: Raltegravir is the first HIV-integrase inhibitor licensed by the FDA. Areas covered in this review: A PubMed search was conducted for all published reports up to 1 May 2010 related to raltegravir pharmacokinetics, pharmacology, drug-drug interactions and clinical studies in HIV-infected patients. Also included in this review are the updated European and US Prescriber's Information (European Medicines Agency and the FDA) and abstracts from recent international scientific meetings. What the reader will gain: After reading the review, a thorough insight in raltegravir pharmacokinetics and pharmacology will be obtained, as well as an up-to-date overview of all published drug-drug interaction studies. Furthermore, one should be able to make an evidence-based opinion on the drug's clinical efficacy and tolerability. Take home message: Raltegravir is a welcome addition to the antiretroviral drug armamentarium due to its good tolerability, low potential for drug-drug interactions and good clinical efficacy in both treatment-naive and -experienced patients.

引用

页码：1151 / 1160

页数：10

共 50 条

[1] PERINDOPRIL - A REVIEW OF ITS PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY
MACFADYEN, RJ
LEES, KR
REID, JL
[J]. DRUGS, 1990, 39 : 49 - 63
[2] STUDIES WITH NAPROXEN AS TO CLINICAL PHARMACOLOGY AND PHARMACOKINETICS
BOOST, G
[J]. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1975, 25 (NA2): : 281 - 287
[3] Alpinetin: A Review of Its Pharmacology and Pharmacokinetics
Zhao, Ge
Tong, Yue
Luan, Fei
Zhu, Wenjing
Zhan, Chenglin
Qin, Tiantian
An, Weixiao
Zeng, Nan
[J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
[4] Esculetin: A review of its pharmacology and pharmacokinetics
Zhang, Linlin
Xie, Qingxuan
Li, Xiaofang
[J]. PHYTOTHERAPY RESEARCH, 2022, 36 (01) : 279 - 298
[5] GLYCEROL - A REVIEW OF ITS PHARMACOLOGY, PHARMACOKINETICS, ADVERSE REACTIONS, AND CLINICAL USE
FRANK, MSB
HILTY, MD
NAHATA, MC
[J]. PHARMACOTHERAPY, 1981, 1 (02): : 147 - 160
[6] PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING
Calcagno, A.
Bonora, S.
Nozza, S.
Castagna, A.
Ripamonti, D.
D'Avolio, A.
Siccardi, M.
Baietto, L.
Maggiolo, F.
Lazzarin, A.
Di Perri, G.
[J]. INFECTION, 2009, 37 : 69 - 69
[7] HIV-1 integrase inhibitors:: Raltegravir.: Review of its clinical efficacy and pharmacokinetics
Alsina, Placeres M. M.
Conde, Martin M. T.
Tuset Creus, M.
del Cacho, Del Cacho M. E.
Massants Gonzalez, M.
Codina Jane, C.
Ribas Sala, J.
[J]. ATENCION FARMACEUTICA, 2008, 10 (02): : 87 - +
[8] PINDOLOL - A REVIEW OF ITS PHARMACOLOGY, PHARMACOKINETICS, CLINICAL USES, AND ADVERSE-EFFECTS
GOLIGHTLY, LK
[J]. PHARMACOTHERAPY, 1982, 2 (03): : 134 - 147
[9] Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
Vermes, A
Guchelaar, HJ
Dankert, J
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) : 171 - 179
[10] LABETALOL - A REVIEW OF ITS PHARMACOLOGY, PHARMACOKINETICS, CLINICAL USES AND ADVERSE-EFFECTS
MACCARTHY, EP
BLOOMFIELD, SS
[J]. PHARMACOTHERAPY, 1983, 3 (04): : 193 - 219

← 1 2 3 4 5 →